WHO guideline for clinical management of exposure to lead
| Autor Corporativo: | |
|---|---|
| Otros Autores: | |
| Formato: | Libro electrónico |
| Idioma: | Inglés |
| Publicado: |
Geneva :
World Health Organization
[2021]
|
| Edición: | 1st ed |
| Materias: | |
| Ver en Biblioteca Universitat Ramon Llull: | https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009641236006719 |
Tabla de Contenidos:
- Intro
- Contents
- Acknowledgements
- Abbreviations and acronyms
- Executive Summary
- The Guideline
- 01 / Purpose and scope
- 02 / Methods for guideline development
- 2.1 Contributors to the guideline
- 2.2 Identification of priority questions and critical outcomes
- 2.3 Identification and retrieval of evidence
- 2.4 Quality assessment and grading of evidence
- 2.6 Development of recommendations
- 2.7 Good practice statements
- 2.8 Consultation with stakeholders
- 2.9 Document preparation and peer review
- 03 / Results of the review
- 3.1 Guiding principles
- 04 / Background
- 4.1 Principal sources of exposure to lead
- 4.2 Routes of exposure to lead
- 4.3 Toxicokinetics
- 4.4 Toxicity of lead
- 4.5 Toxic effects in relation to blood lead concentrations
- 05 / Diagnosis of lead poisoning
- 06 / Recommendation on the blood lead concentration that should initiate clinical interventions
- 6.1 Introduction
- 6.2 Recommendations for all age groups
- 6.3 Values, equity, feasibility and acceptability of a 5 µg/dL threshold value
- 6.4 Considerations for implementation
- 07 / Recommendations for specific treatment interventions
- 7.1 Gastrointestinal decontamination after ingestion of a lead foreign body or other lead-containing material
- 7.2 Nutritional interventions in children and in pregnant and lactating women exposed to lead
- 7.3 Chelation therapy in individuals exposed to lead
- 08 / Integration and implementation of the recommendations in the management of lead poisoning
- 8.1 Taking a history to Identify the source(s) of exposure
- 8.2 Evaluation of the severity of exposure
- 8.3 Reduction and termination of exposure, including improving nutrition
- 8.4 Chelation therapy
- 8.5 Supportive measures
- 8.6 Follow-up
- 09 / Research gaps
- 9.1 Gastrointestinal decontamination.
- 9.2 Nutritional interventions
- 9.3 Chelation therapy
- 10 / Considerations for implementation of the guideline
- References
- Annex 1 Members of the WHO Steering Group
- Annex 2 Guideline Development Group
- Annex 3
- Research questions and critical and important outcomes
- Annex 4 External reviewers
- Annex 5Flowcharts summarizing aspects of patient management.
